- Home
- MRCC vs PBYI Comparison
MRCC vs PBYI Comparison
Compare MRCC & PBYI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MRCC
- PBYI
- Stock Information
- Founded
- MRCC 2011
- PBYI 2010
- Country
- MRCC United States
- PBYI United States
- Employees
- MRCC N/A
- PBYI N/A
- Industry
- MRCC Investment Managers
- PBYI Biotechnology: Pharmaceutical Preparations
- Sector
- MRCC Finance
- PBYI Health Care
- Exchange
- MRCC Nasdaq
- PBYI Nasdaq
- Market Cap
- MRCC 155.1M
- PBYI 171.7M
- IPO Year
- MRCC 2012
- PBYI N/A
- Fundamental
- Price
- MRCC $7.57
- PBYI $4.64
- Analyst Decision
- MRCC Hold
- PBYI Strong Buy
- Analyst Count
- MRCC 1
- PBYI 1
- Target Price
- MRCC $8.00
- PBYI $7.00
- AVG Volume (30 Days)
- MRCC 66.0K
- PBYI 648.1K
- Earning Date
- MRCC 11-11-2025
- PBYI 11-06-2025
- Dividend Yield
- MRCC 13.42%
- PBYI N/A
- EPS Growth
- MRCC N/A
- PBYI 434.29
- EPS
- MRCC 0.09
- PBYI 0.97
- Revenue
- MRCC $51,229,000.00
- PBYI $238,062,000.00
- Revenue This Year
- MRCC N/A
- PBYI N/A
- Revenue Next Year
- MRCC N/A
- PBYI N/A
- P/E Ratio
- MRCC $84.33
- PBYI $4.76
- Revenue Growth
- MRCC N/A
- PBYI 8.63
- 52 Week Low
- MRCC $5.96
- PBYI $2.32
- 52 Week High
- MRCC $8.85
- PBYI $6.07
- Technical
- Relative Strength Index (RSI)
- MRCC 72.81
- PBYI 49.99
- Support Level
- MRCC $7.43
- PBYI $4.49
- Resistance Level
- MRCC $7.66
- PBYI $5.22
- Average True Range (ATR)
- MRCC 0.13
- PBYI 0.26
- MACD
- MRCC -0.02
- PBYI -0.12
- Stochastic Oscillator
- MRCC 76.92
- PBYI 22.33
About MRCC Monroe Capital Corporation
Monroe Capital Corp is a speciality finance company focused on providing financing to lower middle-market companies, in the U.S. and Canada. The company provides customized financing solutions focused on senior, unitranche, and junior secured debt and unsecured subordinated debt and equity, including equity co-investments in preferred and common stock and warrants.
About PBYI Puma Biotechnology Inc
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes inventive products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also it develops alisertib. Alisertib is a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis resulting into apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.